

LOW PREVALENCE OF HEPATITIS E VIRUS IN TYPE II MIXED CRYOGLOBULINEMIA

Piero Marson, Carla Donadel, Mariangela Vicarioto, Giustina De Silvestro

Blood Transfusion Service, Hospital of Padua, Padua, Italy

Sir,

the relationship between hepatotropic viruses and mixed cryoglobulinemia (MC) has long been studied because of the frequent association of this lymphoproliferative disorder with chronic liver disease.¹

Initially, a link with hepatitis B virus (HBV) was proposed, but a recent survey of a large series of cryoglobulinemic patients did not support this theory.² Moreover, evidence of hepatitis A virus (HAV) exposure has occasionally been recorded in MC.³ At present, MC is considered a hepatitis C virus (HCV)-related disease since anti-HCV seroprevalence is very high (>80%) and HCV-RNA has been demonstrated in plasma and cryoprecipitate, as well as in blood and bone marrow mononuclear cells from MC patients.⁴

Another hepatotropic virus, i.e. hepatitis E virus (HEV), is the major etiological agent of non parenteral non-A, non-B hepatitis; it is responsible for large epidemics in developing countries and sporadic disease outbreaks in the industrialized world.⁵ Although hepatitis E is a typical feco-orally-transmitted infection, other routes of contagion can be hypothesized, owing to the high prevalence of anti-HEV antibodies found in polytransfused and hemodialysis patients.^{6,7} Moreover, a striking association between HCV and HEV infections was demonstrated in some selected populations.^{8,9}

Therefore, we examined anti-HEV serology in 40 anti-HCV positive (second generation test) patients affected with type II MC (7 males and 33 females; mean age of 59 yrs, range 29-78; cryoprecipitate composed of monoclonal IgM κ plus polyclonal IgG in all cases).

Detection of anti-HEV antibodies was carried out by a commercially available EIA kit (Abbott

Laboratories, North Chicago, IL, USA), utilizing two recombinant antigens (SG-3 and 8-5) derived from the structural region of the Burmese HEV strain expressed in *Escherichia coli*.

One female patient, aged 62 yrs, suffering predominantly from severe cryoglobulinemic peripheral neuropathy, was found to be HEV seropositive (serum sample optical density/cut-off repeatedly >1.50). Interestingly, this patient at the age of 45 and before the occurrence of MC had a history of acute jaundice, which could be attributed, at least in a presumptive way, to a community-acquired sporadic HEV infection. In fact, at that time no apparent risk for HAV was retrospectively documented and serum markers of prior HBV exposure are at present absent, thus making a diagnosis of HAV or HBV infection unlikely. In addition, this episode of acute jaundice could not be ascribed to HCV infection since most patients with acute hepatitis C are quite asymptomatic.¹⁰

This fact may be indirectly inferred by considering all the other patients belonging to our series, none of whom had a history of previous jaundice, thus indicating a silent clinical course for acute HCV infection. The lasting persistence of anti-HEV antibodies that we hypothesize in our HEV seropositive patient is in agreement with some data demonstrating that IgG anti-HEV can be detected for long periods, even more than 14 yrs after the HEV exposure.¹¹

According to our results, although in MC HEV seroprevalence seems to be higher than in the normal healthy Italian population (2.50% vs 0.74%),¹² it can be concluded that HEV infection is documented only occasionally in this HCV-related lymphoproliferative disorder. Moreover, the previously described association

between HCV and HEV infection can be ruled out, at least in type II MC patients.

References

1. Mussini C, Ghini M, Zanni G, et al. Cryoglobulinemia: a monoclonal gammopathy? *Haematologica* 1993; 78:255-6.
2. Galli M, Monti G, Invernizzi F, et al. Hepatitis B virus related markers in secondary and in essential mixed cryoglobulinemias: a multicentric study of 596 cases. *Ann Ital Med Intern* 1992; 7:209-14.
3. Inman RD, Hodge M, Johnston MEA, Wright J, Heathcote J. Arthritis, vasculitis and cryoglobulinemia associated with relapsing hepatitis A virus infection. *Ann Intern Med* 1986; 105:700-3.
4. Gabrielli A, Manzin A, Candela M, et al. Active hepatitis C virus infection in bone marrow and peripheral blood mononuclear cells from patients with mixed cryoglobulinaemia. *Clin Exp Immunol* 1994; 97:87-93.
5. Fields HA, Favorov MO, Margolis HS. The hepatitis E virus: a review. *J Clin Immunology* 1993; 16:215-23.
6. Wang CH, Flehmig B, Moeckli R. Transmission of hepatitis E virus by transfusion? *Lancet* 1993; 341:825-6.
7. Halfon P, Ouzan M, Khiri H, et al. High prevalence of hepatitis E virus antibody in haemodialysis patients. *Lancet* 1994; 344:746.
8. Thomas DL, Mahley RW, Badur S, Palaoglu KE, Quinn TC. Epidemiology of hepatitis E virus infection in Turkey. *Lancet* 1993; 341:1561-62.
9. Pisanti FA, Coppola A, Galli C. Association between hepatitis C and hepatitis E viruses in southern Italy. *Lancet* 1994; 344:746-7.
10. Weiland O, Schvarcz R. Hepatitis C: virology, epidemiology, clinical course, and treatment. *Scand J Gastroenterol* 1992; 27:337-42.
11. Khuroo MS, Kamili S, Dar MY, Moekli R, Jameel S. Hepatitis E and long-term antibody status. *Lancet* 1993; 341:1355.
12. Zanetti AR, Dawson GJ, and the Study Group of Hepatitis E. Hepatitis type E in Italy: a sero-epidemiological survey. *J Med Virol* 1994; 42:318-20.